OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
UTRECHT, The Netherlands, Aug. 09, 2017 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16, 2017 at 9:45 a.m. ET.
A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ lead bispecific antibody candidate, MCLA-128, is expected to begin a Phase 2 combination trial in the second half of 2017 in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in Europe in gastric, ovarian, endometrial and non-small cell lung cancers. Merus’ second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145 designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in collaboration with Incyte Corporation.
Contacts: Media: Eliza Schleifstein +1 973 361 1546 [email protected] Investors: Kimberly Minarovich +1 646 368 8014 [email protected]
